FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2766545681> ?p ?o ?g. }

• W2766545681 endingPage "98416" @default.
• W2766545681 startingPage "98405" @default.
• W2766545681 abstract "// Takayuki Ninomiya 1 , Toshiaki Ohara 1, 2 , Kazuhiro Noma 1 , Yuki Katsura 1 , Ryoichi Katsube 1 , Hajime Kashima 1 , Takuya Kato 1 , Yasuko Tomono 3 , Hiroshi Tazawa 1, 4 , Shunsuke Kagawa 1 , Yasuhiro Shirakawa 1 , Fumiaki Kimura 5 , Ling Chen 6, 7 , Tomonari Kasai 6 , Masaharu Seno 6 , Akihiro Matsukawa 2 and Toshiyoshi Fujiwara 1 1 Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan 2 Department of Pathology and Experimental Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan 3 Shigei Medical Research Institute, Okayama, Japan 4 Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan 5 Department of Internal Medicine, Tamano General Hospital, Okayama, Japan 6 Department of Medical and Bioengineering Science, Okayama University Graduate School of Natural Science and Technology, Okayama, Japan 7 Department of Pathology, Tiajin Central Hospital of Gynecology Obstetrics, Tianjin, People’s Republic of China Correspondence to: Toshiaki Ohara, email: t_ohara@cc.okayama-u.ac.jp Keywords: cancer stem cells, induced pluripotent stem cells, iron chelators, stemness Received: May 16, 2017      Accepted: September 23, 2017      Published: October 12, 2017 ABSTRACT Adequate iron levels are essential for human health. However, iron overload can act as catalyst for the formation of free radicals, which may cause cancer. Cancer stem cells (CSCs), which maintain the hallmark stem cell characteristics of self-renewal and differentiation capacity, have been proposed as a driving force of tumorigenesis and metastases. In the present study, we investigated the role of iron in the proliferation and stemness of CSCs, using the miPS-LLCcm cell model. Although the anti-cancer agents fluorouracil and cisplatin suppressed the proliferation of miPS-LLCcm cells, these drugs did not alter the expression of stemness markers, including Nanog, SOX2, c-Myc, Oct3/4 and Klf4. In contrast, iron depletion by the iron chelators deferasirox and deferoxamine suppressed the proliferation of miPS-LLCcm cells and the expression of stemness markers. In an allograft model, deferasirox inhibited the growth of miPS-LLCcm implants, which was associated with decreased expression of Nanog and Sox2. Altogether, iron appears to be crucial for the proliferation and maintenance of stemness of CSCs, and iron depletion may be a novel therapeutic strategy to target CSCs." @default.
• W2766545681 created "2017-11-10" @default.
• W2766545681 creator A5001396536 @default.
• W2766545681 creator A5001657741 @default.
• W2766545681 creator A5008094618 @default.
• W2766545681 creator A5015421086 @default.
• W2766545681 creator A5018726876 @default.
• W2766545681 creator A5023513346 @default.
• W2766545681 creator A5027121695 @default.
• W2766545681 creator A5043442664 @default.
• W2766545681 creator A5049100460 @default.
• W2766545681 creator A5052371333 @default.
• W2766545681 creator A5055129091 @default.
• W2766545681 creator A5057625419 @default.
• W2766545681 creator A5068717107 @default.
• W2766545681 creator A5075241700 @default.
• W2766545681 creator A5076268036 @default.
• W2766545681 creator A5078170508 @default.
• W2766545681 creator A5085355727 @default.
• W2766545681 date "2017-10-12" @default.
• W2766545681 modified "2023-10-16" @default.
• W2766545681 title "Iron depletion is a novel therapeutic strategy to target cancer stem cells" @default.
• W2766545681 cites W1964903539 @default.
• W2766545681 cites W1972677660 @default.
• W2766545681 cites W1975992482 @default.
• W2766545681 cites W1983641075 @default.
• W2766545681 cites W2012582486 @default.
• W2766545681 cites W2016658523 @default.
• W2766545681 cites W2036148514 @default.
• W2766545681 cites W2041685488 @default.
• W2766545681 cites W2051204314 @default.
• W2766545681 cites W2053019542 @default.
• W2766545681 cites W2068305486 @default.
• W2766545681 cites W2068416436 @default.
• W2766545681 cites W2078522367 @default.
• W2766545681 cites W2111511846 @default.
• W2766545681 cites W2112296880 @default.
• W2766545681 cites W2125987139 @default.
• W2766545681 cites W2159607376 @default.
• W2766545681 cites W2160368193 @default.
• W2766545681 cites W2163064788 @default.
• W2766545681 cites W2163292580 @default.
• W2766545681 cites W2164618754 @default.
• W2766545681 cites W2313822720 @default.
• W2766545681 cites W2341898654 @default.
• W2766545681 cites W249545773 @default.
• W2766545681 cites W2506464204 @default.
• W2766545681 cites W2515099145 @default.
• W2766545681 cites W2515243765 @default.
• W2766545681 cites W2529891814 @default.
• W2766545681 cites W2587496087 @default.
• W2766545681 doi "https://doi.org/10.18632/oncotarget.21846" @default.
• W2766545681 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5716739" @default.
• W2766545681 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29228699" @default.
• W2766545681 hasPublicationYear "2017" @default.
• W2766545681 type Work @default.
• W2766545681 sameAs 2766545681 @default.
• W2766545681 citedByCount "33" @default.
• W2766545681 countsByYear W27665456812018 @default.
• W2766545681 countsByYear W27665456812019 @default.
• W2766545681 countsByYear W27665456812020 @default.
• W2766545681 countsByYear W27665456812021 @default.
• W2766545681 countsByYear W27665456812022 @default.
• W2766545681 countsByYear W27665456812023 @default.
• W2766545681 crossrefType "journal-article" @default.
• W2766545681 hasAuthorship W2766545681A5001396536 @default.
• W2766545681 hasAuthorship W2766545681A5001657741 @default.
• W2766545681 hasAuthorship W2766545681A5008094618 @default.
• W2766545681 hasAuthorship W2766545681A5015421086 @default.
• W2766545681 hasAuthorship W2766545681A5018726876 @default.
• W2766545681 hasAuthorship W2766545681A5023513346 @default.
• W2766545681 hasAuthorship W2766545681A5027121695 @default.
• W2766545681 hasAuthorship W2766545681A5043442664 @default.
• W2766545681 hasAuthorship W2766545681A5049100460 @default.
• W2766545681 hasAuthorship W2766545681A5052371333 @default.
• W2766545681 hasAuthorship W2766545681A5055129091 @default.
• W2766545681 hasAuthorship W2766545681A5057625419 @default.
• W2766545681 hasAuthorship W2766545681A5068717107 @default.
• W2766545681 hasAuthorship W2766545681A5075241700 @default.
• W2766545681 hasAuthorship W2766545681A5076268036 @default.
• W2766545681 hasAuthorship W2766545681A5078170508 @default.
• W2766545681 hasAuthorship W2766545681A5085355727 @default.
• W2766545681 hasBestOaLocation W27665456811 @default.
• W2766545681 hasConcept C3018419874 @default.
• W2766545681 hasConcept C509550671 @default.
• W2766545681 hasConcept C556039675 @default.
• W2766545681 hasConcept C71924100 @default.
• W2766545681 hasConcept C74909509 @default.
• W2766545681 hasConceptScore W2766545681C3018419874 @default.
• W2766545681 hasConceptScore W2766545681C509550671 @default.
• W2766545681 hasConceptScore W2766545681C556039675 @default.
• W2766545681 hasConceptScore W2766545681C71924100 @default.
• W2766545681 hasConceptScore W2766545681C74909509 @default.
• W2766545681 hasIssue "58" @default.
• W2766545681 hasLocation W27665456811 @default.
• W2766545681 hasLocation W27665456812 @default.
• W2766545681 hasLocation W27665456813 @default.
• W2766545681 hasLocation W27665456814 @default.

• next